SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
CognitiveFDA-approvedVendors pending
FDA-approvedVendors pendingFacts verified · 2026-05-25

Selank

Also known as tuftsin analog, tp-7 · Wikipedia

Selank is a synthetic heptapeptide anxiolytic derived from the immunomodulator tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro stabilizing tail. Developed at the Russian Academy of Sciences alongside Semax, it is approved in Russia as an intranasal solution for generalized anxiety disorder and asthenic conditions. Outside Russia it is handled as a research chemical with no regulatory approval. Reported effects include reduction of anxiety symptoms without sedation, dependence, or withdrawal characteristic of benzodiazepines, plus pro-cognitive and immunomodulatory actions. Also known as Tuftsin analog and TP-7.

—

best

price

—

per

mg

—

vendors

tracked

FDA-approved

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) couples the immunomodulatory tetrapeptide tuftsin to a Pro-Gly-Pro tail for protease stability. Its anxiolytic action involves subtype-selective allosteric modulation of GABA-A receptors and altered expression of GABAergic genes in neuronal cell lines (https://pubmed.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) couples the immunomodulatory tetrapeptide tuftsin to a Pro-Gly-Pro tail for protease stability. Its anxiolytic action involves subtype-selective allosteric modulation of GABA-A receptors and altered expression of GABAergic genes in neuronal cell lines (https://pubmed.ncbi.nlm.nih.gov/26924987/ ; https://pubmed.ncbi.nlm.nih.gov/30255741/), inhibition of enkephalin-degrading enzymes raising endogenous enkephalin tone (https://pubmed.ncbi.nlm.nih.gov/11550013/), upregulation of hippocampal BDNF, and Th1/Th2 cytokine balance shifts in patients with anxiety-asthenic disorders (https://pubmed.ncbi.nlm.nih.gov/18577961/). Unlike benzodiazepines it does not produce sedation, amnesia, or tolerance, and in chronic-stress models it potentiates the anxiolytic effect of diazepam without producing benzodiazepine-like dependence or withdrawal (https://pmc.ncbi.nlm.nih.gov/articles/PMC5322660/).

Pharmacokinetic properties

Half-life

Plasma half-life ~2-3 minutes; behavioral/anxiolytic effects persist 12-24 hours via downstream neuroplastic changes

Routes

intranasal · subcutaneous

Bioavailability

Intranasal is the standard route in Russian clinical use; provides nose-to-brain delivery. Oral bioavailability is negligible due to peptidase degradation.

Amino-acid sequence

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Use & research dosing

Anxiety ReliefFocusMood Support

The Russian-approved formulation is a 0.15% intranasal solution. In published clinical reports and self-experimentation protocols the most common range is 250-900 mcg/day intranasally, split into 2-3 administrations, typically as a 10-14 day course. Higher daily totals (up to ~1,800 mcg) have been used in Russian inpatient studies. There is no FDA- or EMA-approved formulation and no validated Western clinical dose; research framing only.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Unlike benzodiazepines, Selank does not produce dependence, withdrawal, or amnesia in available preclinical and Russian clinical studies. Most efficacy data are Russian-language; large Western RCTs are absent. Frequently discussed alongside Semax (same institute, distinct GABAergic mechanism) and BPC-157 in user stacks, though no controlled human stack data exist.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Not FDA- or EMA-approved; research chemical outside Russia
  • Pregnancy and lactation safety not established; avoid
  • Theoretical additive sedation when combined with benzodiazepines, alcohol, or other CNS depressants
  • Caution with other GABAergic agents (gabapentinoids, barbiturates) due to potential interaction
  • Quality and sterility of research-grade intranasal solutions vary widely
  • Avoid in untreated psychiatric conditions without supervision
  • Pediatric use outside Russian product labels is not supported by Western evidence

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/30255741/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/26924987/
  3. [03]https://pubmed.ncbi.nlm.nih.gov/11550013/
  4. [04]https://pubmed.ncbi.nlm.nih.gov/18577961/
  5. [05]https://pmc.ncbi.nlm.nih.gov/articles/PMC5322660/

Facts verified

2026-05-25

Confidence

medium

What this means

  • evidence base is primarily Russian-language; limited Western RCT replication

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.